In a reversal from last year, CVS will begin covering Eli Lilly's Zepbound and Foundayo in its standard prescription plan, a win for GLP-1 patients.

Zepbound’s preferred-tier reinstatement suggests improved net pricing and signals renewed willingness to broaden injectable anti-obesity access under commercial benefit designs. Lifting Foundayo’s ...

Coverage of Lilly’s obesity medications is expanding in the near future. Here’s why that matters.

CVS Caremark is putting Eli Lilly’s obesity drug Zepbound back on some commercial formularies starting Oct. 1, reversing a mid-2025 decision that had nudged many patients toward rival GLP-1 ...

CVS Caremark will resume covering the weight loss drug Zepbound this year after it removed it from its list of covered ...

The top pharmacy benefit manager (PBM) in the U.S., CVS Caremark, will restore coverage to obesity products from Eli Lilly, ...

CVS reverses Zepbound coverage on commercial formularies after patient backlash and a class-action lawsuit alleging ERISA violations.

Eli Lilly (LLY) stock is in focus as CVS Health (CVS) restores Zepbound coverage effective Oct 1, 2026, and adds Foundayo to ...

The agreement includes Lilly’s new pill Foundayo and restores coverage for Zepbound, erasing what had been a commercial edge for rival Novo Nordisk.

The FDR outcome directs FDA divisions to finalize labeling with the sponsor, reversing the prior CRL trajectory and ...

CVS Caremark will expand the use of lower-cost biosimilars across multiple therapeutic categories effective July 1. In addition to changes involving Stelara, CVS Caremark is expanding biosimilar ...